Protagonist swings to $162.8M Q2 profit on Takeda opt-out and ICOTYDE approval

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read

Key Changes

• high

  Revenue surged 3749.2% to $213.5M, driven by a $200M Takeda opt-out payment and a $50M JNJ milestone for ICOTYDE approval.

  MD&A: Operating results verify on EDGAR →
• high

  Net income swung from a $34.8M loss to a $162.8M profit, with diluted EPS of $2.29.

  MD&A: Net income verify on EDGAR →
• high

  ICOTYDE (icotrokinra) received FDA approval in March 2026 for moderate-to-severe plaque psoriasis, triggering a $50M milestone.

  MD&A: ICOTYDE approval verify on EDGAR →